Morgan Stanley IM: Psychedelics
Psychedelics have the potential to fundamentally reshape how we think about and treat not only mental illness but a host of other conditions as well. Counterpoint Global investigates how psychedelic therapy works, the potential wide-spread impact of this innovative treatment, and the roadblocks to medical adoption.01.08.2022 | 06:40 Uhr
- The number of mood disorders and suicide-related events has increased significantly in the last decade, exacerbated by the stress of modern life and the isolation brought on by COVID. However, there have been no truly new drugs for depression since the 1980s when Prozac and other selective serotonin reuptake inhibitors (SSRIs) came to market.
- Psychedelics could fundamental change how mental health disorders are treated. Instead of aiming to mask or mute symptoms with chronic drug intake, like SSRIs, psychedelic-assisted therapy can change a patient’s basic outlook on life over the course of one to a handful of sessions.
- Beyond mental illness, psychedelics could offer a physiologically safe and non-addictive alternative treatment for multiple indications including pain-related conditions.
Click on the PDF to read the full report.